{
    "nctId": "NCT00287534",
    "briefTitle": "Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.",
    "officialTitle": "A Prospective, Multi-Centre, Randomised, Open Parallel Group Study to Compare the Effectiveness and Compatibility of ARIMIDEX (ZD 1033) With NOLVADEX After a Prior 2 Years' Treatment With Tamoxifen in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 1059,
    "primaryOutcomeMeasure": "To assess the difference in disease-free survival between post-menopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastrozole and those who continued to receive tamoxifen",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Signed informed consent,\n* Post-menopausal women \u226475 years,\n* histologically confirmed invasive breast carcinoma (no distant metastases),\n* positive hormone receptor status,\n* continuous 2-year adjuvant tamoxifen therapy 20 mg/30 mg with 4 weeks after primary surgery\n\nExclusion Criteria:\n\n* menopause status maintained by medication,\n* pre-operative chemotherapy or hormone therapy or radiation therapy,\n* relapse or second carcinoma or previous cancerous disease,\n* breast carcinoma in situ,\n* simultaneous carcinoma of the opposite side or secondary breast,\n* 10 or more tumour-infiltrated lymph nodes.\n* serious accompanying diseases",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}